Share
While limited in scope, a 2022 meta-analysis of patient outcomes reveals that compounded hormones provide real benefits to patients -- and also found that compounded hormones pose no increased risk compared to FDA-approved products.
As part of its commission, NASEM was to review the body of patient-outcome studies for compounded hormones. NASEM chose to ignore that data, instead selecting only 13 studies to include in its report, mostly featuring hormones that are not among the most commonly prescribed. (Studies that matched their predetermined outcome?)
This report, published in Menopause, the journal of the North American Menopause Society, is exactly the kind of unbiased research that NASEM should have done but didn't.
Hear their stories, in their own words. Protect their access to compounded hormones.
On this page, we can only touch on the data that demonstrates the importance of compounded hormones to the lives of millions of women in this country. While the decision to take this vital therapy from patients and physicians might be profitable for the big pharmaceutical companies, it will be disastrous for the millions of patients that those same pharmaceutical companies cannot serve!
We encourage the appropriate committees in both the House and Senate to hold hearings on this critical issue.
Preserve compounded hormones.
Explore our interactive map that demonstrates the importance of compounded hormones to patients all across the country. Filter these first-hand accounts by state to see just how vital compounded hormones are.